Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive (Ph(+) ALL) cases and immunotherapeutic approaches, including...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Moujalled, Donia M., Hanna, Diane T., Hediyeh-zadeh, Soroor, Pomilio, Giovanna, Brown, Lauren, Litalien, Veronique, Bartolo, Ray, Fleming, Shaun, Chanrion, Maïa, Banquet, Sébastien, Maragno, Ana-Leticia, Kraus-Berthier, Laurence, Schoumacher, Marie, Mullighan, Charles G., Georgiou, Angela, White, Christine A., Lessene, Guillaume, Huang, David C. S., Roberts, Andrew W., Geneste, Olivier, Rasmussen, Lorna, Davis, Melissa J., Ekert, Paul G., Wei, Andrew, Ng, Ashley P., Khaw, Seong L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322969/
https://ncbi.nlm.nih.gov/pubmed/32569380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001416
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak